Kura Oncology (KURA) COO sells shares to cover RSU tax bill

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported a small stock sale related to tax withholding. On 01/27/2026, she sold 1,813 shares of common stock at $8.4607 per share in a transaction coded “S.”

The filing explains this was a sell-to-cover for taxes tied to the vesting of a restricted stock unit granted on 01/26/2022. After this transaction, Ford beneficially owned 153,560 shares of Kura Oncology common stock in direct form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FORD KATHLEEN

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		S		1,813	D(1)	$8.4607	153,560	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.

	Teresa Bair, Attorney-in-fact for Kathleen Ford	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kura Oncology (KURA) disclose about Kathleen Ford’s recent share sale?

Kura Oncology disclosed that Chief Operating Officer Kathleen Ford sold 1,813 shares of common stock at $8.4607 per share. The sale was reported as a routine Form 4 insider transaction with shares remaining directly owned after the sale.

Why did Kura Oncology COO Kathleen Ford sell 1,813 KURA shares?

The 1,813 Kura Oncology shares were sold to cover taxes due on the vesting of a restricted stock unit granted on January 26, 2022. This type of sell-to-cover is a common administrative transaction for equity compensation.

How many Kura Oncology (KURA) shares does Kathleen Ford hold after the transaction?

After the reported transaction, Kathleen Ford beneficially owned 153,560 shares of Kura Oncology common stock directly. This reflects her holdings following the 1,813-share sale executed on January 27, 2026 at $8.4607 per share.

What was the price and date of Kathleen Ford’s Kura Oncology share sale?

Kathleen Ford sold 1,813 Kura Oncology common shares on January 27, 2026, at a price of $8.4607 per share. The sale was coded as an “S” transaction and described as a sell-to-cover for tax withholding.

Is the Kathleen Ford Form 4 for Kura Oncology a routine insider tax sale?

Yes. The Form 4 states the transaction was a sell-to-cover for taxes associated with an RSU vesting dated January 26, 2022. Such transactions typically occur automatically to satisfy tax obligations on equity compensation.